EDIT - Company ID 0001650664
The table below shows Editas Medicine, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $2.83M | $7.54M | $3.58M | $4.66M | $61.00K | $513.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $17.60M | $19.77M | $16.18M | $26.59M | $47.64M | $54.21M |
Editas Medicine, Inc. reported annual revenue of $40.52M for fiscal year 2025. That is up 25.4% from $32.31M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $6.05M (FY 2016) to $40.52M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $10.23M |
| $12.32M |
| $12.86M |
| $13.38M |
| $18.09M |
| $18.21M |
| Operating income | -$25.00M | -$24.55M | -$51.54M | -$76.16M | -$65.67M | -$71.90M |
| Income tax | - | - | - | - | - | - |
| Net income | -$24.98M | -$25.12M | -$53.23M | -$76.09M | -$62.14M | -$67.61M |
| EPS (diluted) | -$0.26 | -$0.28 | -$0.63 | -$0.92 | -$0.75 | -$0.82 |